← All trials
NCT04410445
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2020
- Primary completion
- Jul 31, 2027
- Completion date
- Jul 31, 2027
- First posted
- Jun 1, 2020
- Last posted
- Jun 1, 2020
- Enrollment
- 950
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nektar TherapeuticsLead sponsor
- Nektar TherapeuticsStudy director
- Bristol-Myers SquibbCollaborator
- Nektar TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.